3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Tumor-Agnostic
3
Thoracic
3
Head & Neck
3
Genitourinary
3
Other solid neoplasm
2
Gynecologic
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Multiple Myeloma
4
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Interventions
Dexamethasone
33
Lenalidomide
14
pomalidomide
12
daratumumab
12
Bortezomib
12
venetoclax
7
Cyclophosphamide
7
isatuximab
6
Therapeutics
6
trametinib
4
carfilzomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
fludarabine
3
dabrafenib
3
Vemurafenib
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Drug Therapy
3
Denosumab
3
Ciprofloxacin
3
Calcium Dobesilate
3
ridaforolimus
2
pembrolizumab
2
molibresib
2
liposomal amphotericin B
2
fludarabine phosphate
2
cobimetinib
2
afuresertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Immunotherapy
×
Plasma cell
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled